Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Igor Puzanov

Showing results (181-190 of 208) with videos related to

Pageof 21
Sort By:
Neuro-Oncology|April 21, 2021
Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)Hussein A Tawbi, Peter A Forsyth, F Stephen Hodi, et al.
The Lancet. Oncology|November 14, 2021
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 studyHussein A Tawbi, Peter A Forsyth, F Stephen Hodi, et al.
Cancer Immunology Research|September 28, 2016
Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 BlockadeDouglas B Johnson, Garrett M Frampton, Matthew J Rioth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2015
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced MelanomaRobert H I Andtbacka, Howard L Kaufman, Frances Collichio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2021
Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced MelanomaYana G Najjar, Dustin McCurry, Huang Lin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanomaKerstin Trunzer, Anna C Pavlick, Lynn Schuchter, et al.
Journal for Immunotherapy of Cancer|March 3, 2026
Where is the data? Delayed and chronic irAE surveillance and management after cessation of ICIs: expert insights from SITC on survivorship care and the need for long-term dataTessa F Flores, Emily S Tonorezos, Shailender Bhatia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 23, 2022
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced MelanomaJason A Chesney, Antoni Ribas, Georgina V Long, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2018
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice GuidelineJulie R Brahmer, Christina Lacchetti, Bryan J Schneider, et al.
Journal of Translational Medicine|December 2, 2015
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014Paolo A Ascierto, Michael Atkins, Carlo Bifulco, et al.
Pageof 21

Showing results (181-190 of 208) with videos related to

Sort By:
Pageof 21
Neuro-Oncology|April 21, 2021
Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)Hussein A Tawbi, Peter A Forsyth, F Stephen Hodi, et al.
The Lancet. Oncology|November 14, 2021
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 studyHussein A Tawbi, Peter A Forsyth, F Stephen Hodi, et al.
Cancer Immunology Research|September 28, 2016
Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 BlockadeDouglas B Johnson, Garrett M Frampton, Matthew J Rioth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2015
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced MelanomaRobert H I Andtbacka, Howard L Kaufman, Frances Collichio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2021
Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced MelanomaYana G Najjar, Dustin McCurry, Huang Lin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanomaKerstin Trunzer, Anna C Pavlick, Lynn Schuchter, et al.
Journal for Immunotherapy of Cancer|March 3, 2026
Where is the data? Delayed and chronic irAE surveillance and management after cessation of ICIs: expert insights from SITC on survivorship care and the need for long-term dataTessa F Flores, Emily S Tonorezos, Shailender Bhatia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 23, 2022
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced MelanomaJason A Chesney, Antoni Ribas, Georgina V Long, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2018
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice GuidelineJulie R Brahmer, Christina Lacchetti, Bryan J Schneider, et al.
Journal of Translational Medicine|December 2, 2015
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014Paolo A Ascierto, Michael Atkins, Carlo Bifulco, et al.
Pageof 21